Clinical Trials Directory

Trials / Completed

CompletedNCT05257057

Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome

Status
Completed
Phase
Study type
Observational
Enrollment
91 (actual)
Sponsor
WellSpan Health · Academic / Other
Sex
Female
Age
18 Years – 99 Years
Healthy volunteers
Accepted

Summary

Given that there is a significant prevalence of Lynch syndrome among patients with endometrial cancer (about 5% of patients with endometrial cancer), and given there is a known risk of endometrial cancer among patients with endometrial hyperplasia (40% risk of pre-existing occult cancer with endometrial intraepithelial neoplasia), it is hypothesized that a diagnosis of endometrial hyperplasia may herald on-going risk of harboring a Lynch Syndrome gene mutation. The purpose of this study is to examine endometrial hyperplasia specimens and compare the frequency of Lynch Syndrome gene mutations between endometrial hyperplasia and endometrial cancer subjects. This will provide a rationale and opportunity for earlier screening, and reduce colon cancer morbidity and mortality secondary to the Lynch syndrome gene.

Detailed description

This is an observational cohort study. Tissue specimens obtained that have been labeled with the diagnosis of endometrial hyperplasia will be identified and their chart reviewed for demographic date of age, race, body mass index, and co-morbidities. The specimen will then be tested via immunohistochemistry for the mismatch repair proteins MLH1, PMS2, MSH2, or MSH 6. Their absence is indicative of Lynch Syndrome. Statistical analysis will then be performed to compare the incidence of Lynch syndrome in endometrial hyperplasia with Lynch Syndrome in endometrial cancer.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTImmunohistochemical stainingImmunohistochemistry will be performed on the endometrial tissue specimens

Timeline

Start date
2019-05-08
Primary completion
2023-06-02
Completion
2023-06-02
First posted
2022-02-25
Last updated
2025-03-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05257057. Inclusion in this directory is not an endorsement.